Animal health company Elanco (NYSE:ELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales ...

GREENFIELD, IN / ACCESS Newswire / February 25, 2025 / Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Elanco has struck an agreement to distribute a vaccine that may protect cattle for up to 12 months against bird flu ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.

Elanco Animal Health (NYSE:ELAN – Free Report) had its target price cut by UBS Group from $18.00 to $17.00 in a research note released on Wednesday morning,Benzinga reports. They currently have a buy ...

Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco Animal Health (NYSE:ELAN – Free Report) had its target price trimmed by Barclays from $20.00 to $19.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently ...

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.